| Literature DB >> 31034508 |
Jae Gon Lee1, Dong Soo Han1, Su Vin Jo1, A Reum Lee1, Chan Hyuk Park1, Chang Soo Eun1, Yangsoon Lee2.
Abstract
Adherent-invasive Escherichia coli (AIEC) has been reported as associated with the pathogenesis of inflammatory bowel disease (IBD). We aimed to investigate the characteristics of mucosa-associated E. coli and the clinical significance of AIEC in Korean IBD patients. E. coli strains were isolated from the mucosal tissues of 18 Crohn's disease (CD) patients, 24 ulcerative colitis (UC) patients, and 9 healthy controls (HC). Adhesion, invasion, and survival assays were performed to evaluate phenotypic features of E. coli isolates and to identify AIEC. The presence of virulence genes and cytokine expression were examined using PCR. In addition, data on IBD-related hospitalization were collected. A total of 59 E. coli strains were isolated (25 from CD, 27 from UC, and 7 from HC). The average levels of adhesion, invasion, and survival were higher in E. coli strains from IBD patients than those from HC (adhesion: 1.65 vs. 0.71, p = 0.046; invasion: 1.68 vs. 0.52, p = 0.039; survival: 519.55 vs. 47.55, p = 0.363). Prevalence of AIEC in HC, CD and UC patients was 22.2%, 38.9% and 37.5%, respectively. E. coli isolates from IBD patients had various virulence genes and were associated with increased expression of TNF-α and IL-17. IBD-related hospitalization within 3 years was 18.8% in patients with AIEC and 11.5% in patients without AIEC. E. coli strains from IBD patients showed high levels of adhesion, invasion, and survival. AIEC strains were identified in both CD and UC patients at a similar rate. AIEC may be associated with sustaining inflammation in the pre-existing inflammatory mucosa.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31034508 PMCID: PMC6488085 DOI: 10.1371/journal.pone.0216165
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of the study subjects.
| Variables | HC (n = 9) | CD (n = 18) | UC (n = 24) | |
|---|---|---|---|---|
| Age | 55.0 (37.0–57.0) | 25.0 (22.0–27.0) | 36.0 (26.0–46.0) | |
| Sex | Male | 4 (44.4) | 11 (61.1) | 10 (41.7) |
| Female | 5 (55.6) | 7 (38.9) | 14 (58.3) | |
| Biopsy site | Ileum | 0 (0) | 5 (27.8) | 0 (0) |
| Ileocecal valve | 0 (0) | 7 (38.9) | 3 (12.5) | |
| Colon | 9 (100) | 6 (33.3) | 21 (87.5) | |
| Number of subjects positive for | 6 (66.7) | 16 (88.9) | 19 (79.2) | |
| CD location | Ileal | - | 1 (5.6) | - |
| Colonic | - | 2 (11.1) | - | |
| Ileocolonic | - | 15 (83.3) | - | |
| Isolated upper disease | - | 0 (0) | - | |
| CD behavior | Non-stricturing and non-penetrating | - | 11 (61.1) | - |
| Stricturing | - | 3 (16.7) | - | |
| Penetrating | - | 4 (22.2) | - | |
| UC extent | Proctitis | - | - | 5 (20.8) |
| Left-sided colitis | - | - | 6 (25.0) | |
| Pancolitis | - | - | 13 (54.2) | |
| Disease activity | Active | - | 14 (77.8) | 15 (62.5) |
| Inactive | - | 4 (22.2) | 9 (37.5) | |
| Treatment exposure | Aminosalicylates | - | 12 (66.7) | 15 (62.5) |
| Steroids | - | 10 (55.6) | 3 (12.5) | |
| Thiopurine | - | 13 (72.2) | 7 (29.2) | |
| Anti-TNF agent | - | 6 (33.3) | 0 (0) | |
| Methotrexate | - | 1 (5.6) | 0 (0) | |
HC, healthy control; CD, Crohn’s disease; UC, ulcerative colitis. Values are given as median (interquartile range) or numbers (%).
*Present location/extent when active disease, previous location/extent when inactive disease.
†Simple endoscopic score for Crohn’s disease (SES-CD) and ulcerative colitis endoscopic index of severity (UCEIS) were used to assess the endoscopic activity. SES-CD <3 and UCEIS ≤1 were considered endoscopically inactive diseases.
Fig 1Classification of E. coli isolates.
(A) Isolated E. coli strains from individual study subjects. (B) ERIC-PCR results. Prefex "n_" and "ibd_" represent healthy control and inflammatory bowel disease patients, respectively. Suffix "_A", "_B1", "_B2", and "_D" represent phylotypes. HC, healthy control; CD, Crohn’s disease; UC, ulcerative colitis.
E. coli isolate phylogenetic groups.
| Phylotype | HC (n = 7) | CD (n = 25) | UC (n = 27) | Total (n = 59) |
|---|---|---|---|---|
| A | 0 (0) | 8 (32.0) | 7 (25.9) | 15 (25.4) |
| B1 | 3 (42.9) | 1 (4.0) | 2 (7.4) | 6 (10.2) |
| B2 | 0 (0) | 12 (48.0) | 11 (40.7) | 23 (39.0) |
| D | 4 (57.1) | 4 (16.0) | 7 (25.9) | 15 (25.4) |
HC, healthy control; CD, Crohn’s disease; UC, ulcerative colitis. Values are given as the number (%).
Characteristics of the isolated E. coli strains.
| Characteristics | Grade of adhesion | Invasion level | Survival level | ||||
|---|---|---|---|---|---|---|---|
| Reference strains | K-12 | 0.05 ± 0.04 | - | 0.05 ± 0.02 | - | 2.61 ± 1.83 | - |
| LF82 | 1.05 ± 0.58 | 1.05 ± 0.16 | 116.07 ± 22.07 | ||||
| Disease group | HC (n = 7) | 0.71 ± 0.49 | 0.046 | 0.52 ± 0.15 | 0.039 | 47.55 ± 15.74 | 0.363 |
| CD (n = 25) | 1.56 ± 0.87 | 1.33 ± 0.42 | 634.10 ± 244.00 | ||||
| UC (n = 27) | 1.74 ± 1.10 | 2.03 ± 0.34 | 420.86 ± 123.84 | ||||
| IBD (n = 52) | 1.65 ± 0.99 | 1.68 ± 0.27 | 519.55 ± 130.82 | ||||
| Phylotype | A (n = 15) | 2.07 ± 0.03 | 0.064 | 1.88 ± 0.37 | <0.001 | 964.73 ± 374.76 | 0.002 |
| B1 (n = 6) | 1.67 ± 0.42 | 4.16 ± 1.40 | 543.84 ± 294.28 | ||||
| B2 (n = 23) | 1.39 ± 0.19 | 0.93 ± 0.26 | 229.69 ± 125.62 | ||||
| D (n = 15) | 1.20 ± 0.28 | 0.70 ± 0.21 | 290.99 ± 108.00 | ||||
| Inflammation | Absent (n = 18) | 1.72 ± 0.27 | 0.412 | 2.63 ± 0.66 | 0.105 | 289.99 ± 157.98 | 0.001 |
| Present (n = 34) | 1.62 ± 0.16 | 1.18 ± 0.21 | 628.73 ± 177.16 | ||||
| CD behavior | B1 (n = 16) | 1.31 ± 0.20 | 0.074 | 1.62 ± 0.67 | 0.450 | 338.00 ± 158.11 | 0.061 |
| B2/B3 (n = 9) | 2.00 ± 0.29 | 0.89 ± 0.22 | 969.20 ± 545.20 | ||||
HC, healthy control; CD, Crohn’s disease; UC, ulcerative colitis; IBD, inflammatory bowel disease; B1, nonstricturing and nonpenetrating; B2, stricturing; B3, penetrating. Values are given as the mean ± standard error of three independent experiments.
a1, adhesion index ≥1; 2, adhesion index ≥10; 3, adhesion index ≥100
bPercentage of inoculum surviving after 1 h of gentamicin treatment (number of intracellular bacteria / initial inoculum x 100)
cNumber of intracellular bacteria at 24 h post-infection / number of bacteria at 1h post-infection x 100 (%)
Prevalence of adherent-invasive E. coli.
| Characteristics | Number of subjects positive for AIEC (%) | ||
|---|---|---|---|
| Disease group | HC (n = 9) | 2 (22.2) | 0.407 |
| CD (n = 18) | 7 (38.9) | ||
| UC (n = 24) | 9 (37.5) | ||
| Disease activity | Active IBD (n = 29) | 11 (37.9) | 0.618 |
| Inactive IBD (n = 13) | 5 (38.5) | ||
| Treatment exposure | Anti-TNF naïve (n = 36) | 14 (38.9) | 0.587 |
| Anti-TNF experienced (n = 6) | 2 (33.3) | ||
| Thiopurine naïve (n = 22) | 9 (40.9) | 0.470 | |
| Thiopurine experienced (n = 20) | 7 (35.0) | ||
AIEC, adherent-invasive E. coli; HC, healthy control; CD, Crohn’s disease; UC, ulcerative colitis; IBD, inflammatory bowel disease
Virulence genotyping.
| Function | Genes | Number of isolates with virulence genes (%) | |||
|---|---|---|---|---|---|
| HC (n = 7) | CD (n = 25) | UC (n = 27) | |||
| Adhesin | 7 (100) | 25 (100) | 27 (100) | - | |
| 6 (85.7) | 21 (84.0) | 22 (81.5) | 0.952 | ||
| 4 (57.1) | 11 (44.0) | 16 (59.3) | 0.527 | ||
| 1 (14.3) | 3 (12.0) | 5 (18.5) | 0.806 | ||
| 3 (42.9) | 11 (44.0) | 13 (48.1) | 0.943 | ||
| Invasin | 0 (0.0) | 4 (16.0) | 4 (14.8) | 0.532 | |
| 6 (86.0) | 19 (76.0) | 21 (77.8) | 0.860 | ||
| 2 (28.6) | 15 (60.0) | 15 (55.6) | 0.331 | ||
| Siderophore | 4 (57.1) | 19 (76.0) | 17 (63.0) | 0.491 | |
| 4 (57.1) | 16 (64.0) | 18 (66.7) | 0.894 | ||
| Capsule | 2 (28.6) | 16 (64.0) | 14 (51.9) | 0.237 | |
| 1 (14.3) | 9 (36.0) | 6 (22.2) | 0.385 | ||
| Toxin | 7 (100) | 23 (92.0) | 26 (96.3) | 0.631 | |
| 0 (0.0) | 0 (0.0) | 0 (0.0) | - | ||
| 2 (28.6) | 5 (20.0) | 3 (11.1) | 0.475 | ||
| Protectin | 7 (100) | 25 (100) | 27 (100) | - | |
| Miscellaneous | 7 (100) | 23 (92) | 23 (85.2) | 0.459 | |
| 5 (71.4) | 22 (88.0) | 25 (92.6) | 0.304 | ||
| 0 (0.0) | 19 (76.0) | 13 (48.1) | 0.001 | ||
| 5 (71.4) | 14 (56.0) | 17 (63.0) | 0.731 | ||
HC, healthy control; CD, Crohn’s disease; UC, ulcerative colitis
Mutations of the fimH gene in E. coli isolates.
| Strain | Group | Phenotype | Amino acid | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25 | 27 | 70 | 78 | 104 | 119 | 150 | 162 | 163 | 166 | 227 | |||
| K-12 | Reference | non-AIEC | A | V | N | S | P | A | A | D | V | R | R |
| LF82 | Reference | AIEC | A | S | N | ||||||||
| n_38_B1 | HC | AIEC | A | ||||||||||
| n_51_D | HC | AIEC | A | S | N | ||||||||
| ibd_03_A | UC | AIEC | A | ||||||||||
| ibd_06_B2 | CD | AIEC | L | ||||||||||
| ibd_06_D | CD | AIEC | A | V | S | ||||||||
| ibd_07_B2 | CD | AIEC | A | ||||||||||
| ibd_19_B1 | UC | AIEC | A | ||||||||||
| ibd_22_B2 | CD | AIEC | A | S | |||||||||
| ibd_25_1_B2 | UC | AIEC | A | S | N | A | |||||||
| ibd_25_2_B2 | UC | AIEC | A | ||||||||||
| ibd_28_A | CD | AIEC | A | ||||||||||
| ibd_30_D | UC | AIEC | |||||||||||
| ibd_31_1_B2 | UC | AIEC | A | ||||||||||
| ibd_31_2_B2 | UC | AIEC | A | ||||||||||
| ibd_40_A | UC | AIEC | A | ||||||||||
| ibd_49_D | UC | AIEC | A | S | N | ||||||||
| ibd_54_D | UC | AIEC | A | S | N | ||||||||
| ibd_60_A | UC | AIEC | A | ||||||||||
| n_14_D | HC | non-AIEC | |||||||||||
| n_33_B1 | HC | non-AIEC | A | V | |||||||||
| n_33_D | HC | non-AIEC | A | V | |||||||||
| n_46_B1 | HC | non-AIEC | A | ||||||||||
| n_55_D | HC | non-AIEC | |||||||||||
| ibd_02_D | UC | non-AIEC | |||||||||||
| ibd_04_B2 | CD | non-AIEC | S | N | |||||||||
| ibd_08_A | UC | non-AIEC | T | A | N | ||||||||
| ibd_08_D | UC | non-AIEC | |||||||||||
| ibd_09_1_B2 | CD | non-AIEC | L | ||||||||||
| ibd_09_2_B2 | CD | non-AIEC | L | ||||||||||
| ibd_09_3_B2 | CD | non-AIEC | L | ||||||||||
| ibd_16_B1 | CD | non-AIEC | A | ||||||||||
| ibd_16_1_B2 | CD | non-AIEC | A | ||||||||||
| ibd_16_2_B2 | CD | non-AIEC | A | ||||||||||
| ibd_17_B2 | CD | non-AIEC | A | N | |||||||||
| ibd_18_B1 | UC | non-AIEC | A | ||||||||||
| ibd_19_D | UC | non-AIEC | A | S | |||||||||
| ibd_20_1_A | UC | non-AIEC | A | N | |||||||||
| ibd_21_1_D | CD | non-AIEC | |||||||||||
| ibd_21_2_D | CD | non-AIEC | |||||||||||
| ibd_23_D | CD | non-AIEC | A | S | N | ||||||||
| ibd_27_B2 | UC | non-AIEC | A | ||||||||||
| ibd_29_1_B2 | UC | non-AIEC | A | S | |||||||||
| ibd_29_2_B2 | UC | non-AIEC | A | S | |||||||||
| ibd_30_B2 | UC | non-AIEC | L | ||||||||||
| ibd_35_D | UC | non-AIEC | A | N | V | ||||||||
| ibd_37_B2 | UC | non-AIEC | S | N | |||||||||
| ibd_42_B2 | UC | non-AIEC | A | ||||||||||
| ibd_47_B2 | CD | non-AIEC | L | ||||||||||
| ibd_48_A | CD | non-AIEC | A | ||||||||||
| ibd_50_B2 | UC | non-AIEC | |||||||||||
| ibd_56_A | CD | non-AIEC | |||||||||||
| ibd_61_B2 | CD | non-AIEC | L | ||||||||||
Blanks indicate identical to wild type, and only the mutations are shown. Prefex "n_" and "ibd_" represent healthy control and inflammatory bowel disease patients, respectively. Suffix "_A", "_B1", "_B2", and "_D" represent phylotypes. HC, healthy control; CD, Crohn’s disease; UC, ulcerative colitis; AIEC, adherent-invasive E. coli
Fig 2RT-PCR analyses for the expression of cytokines in E. coli-infected cell lines.
The expression of TNF-α (A) and IL-17 (B) was significantly increased by E. coli strains from IBD patients, while the expression of IL-8 (C) and COX-2 (D) was not increased. HC, healthy control; CD, Crohn’s disease; UC, ulcerative colitis; TNF-α, tumor necrosis factor alpha; IL, interleukin; COX-2, cyclooxygenase 2 *Statistically significant (p<0.05).